Immune System Key Ltd.
Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.
It is engaged in discovery and development of innovative treatments for malignant and autoimmune diseases with strong unmet needs. ISK’s assets are based on novel human secreted peptides, which were discovered by the founders. ISK’s lead compound is NerofeTM. NerofeTM was granted by the FDA with orphan drug status for AML treatment and currently is in phase IIa development stage. The company holds 3 worldwide patents on the molecule and applications.
LATEST NEWS
Cooperation with Harvard Medical School (MGH)
ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases
![Lippman-picture-11-02[1]](https://www.immunesk.com/wp-content/uploads/2019/04/Lippman-picture-11-021-460x295.jpg)
Prof. Marc E. Lippman – Famous breast cancer expert (KOL ) has joined ISK Ltd
Marc E. Lippman, MD, MACP FRCP is the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard School of Medicine, and was Chairman of the Department of Medicine from May 2007 to May 2012. He is currently Deputy Director of the Sylvester Comprehensive Cancer Center. Previously Dr. Lippman was the John G. Searle Professor and Chair of Internal Medicine at the University of Michigan. From 1988 through 1999 he was Professor of Medicine and Pharmacology and Chair, Department of Oncology, at Georgetown University in Washington, DC, and served as Director of the Lombardi Cancer Center. Dr. Lippman served as Head of the Medical Breast Cancer Section, Medicine Branch, at the NIH. He completed a Fellowship in
Prof. Rosenblatt, Joseph D, M.D, a KOL in hematology, has joined ISK’s advisory board
Prof. Joseph D Rosenblatt
Joseph D Rosenblatt is Professor of Medicine, Microbiology and Immmunology at the University of Miami Miller School of Medicine , and currently serves as the William Harrington Professor of Hematology and Chief of the University of Miami Division of Hematology.
He previously served as chief of the combined Division of Hematology – Oncology from 2001-2017, when Hematology became a separate Division. Rosenblatt also currently serves as Associate Director for Faculty Development in the Sylvester Comprehensive Cancer Center and previously served as Interim Director of the Sylvester Comprehensive Cancer Center from 2010-2012. From 2001 -2017 he served as Associate Director for Clinical and Translational Research within the Sylvester Comprehensive Cancer Center.
Dr. Rosenblatt joined UM/Sylvester in September 2001 from the
